{
  "id": "d75632d9-e62e-37bb-aa73-22a8cf60aaac",
  "webUrl": "http://ftalphaville.ft.com/marketslive/2019-02-14/",
  "title": "Thursday, 14th February 2019",
  "alternativeTitles": {},
  "provenance": [
    "https://api.ft.com/internalcontent/d75632d9-e62e-37bb-aa73-22a8cf60aaac"
  ],
  "byline": "Bryce Elder",
  "publishedDate": "2019-02-14T11:10:19.000Z",
  "firstPublishedDate": "2019-02-14T11:10:19.000Z",
  "publishReference": "tid_t6jaukpdxr_carousel_1558324988",
  "curatedRelatedContent": [],
  "containedIn": [],
  "canBeDistributed": "yes",
  "canBeSyndicated": "verify",
  "comments": {
    "enabled": true
  },
  "standout": {
    "editorsChoice": false,
    "exclusive": false,
    "scoop": false
  },
  "realtime": true,
  "originatingParty": "FT",
  "_lastUpdatedDateTime": "2019-12-12T15:40:23.376Z",
  "_lastUpdatedVersion": "7e31a715ef987f4138810700061579e58b572501",
  "type": "article",
  "accessLevel": "registered",
  "topper": {},
  "url": "http://ftalphaville.ft.com/marketslive/2019-02-14/",
  "relativeUrl": "http://ftalphaville.ft.com/marketslive/2019-02-14/",
  "_editorialComponents": [],
  "openingHTML": "<p>Live markets commentary from FT.com</p>",
  "annotations": [
    {
      "predicate": "http://www.ft.com/ontology/classification/isClassifiedBy",
      "id": "89d15f70-640d-11e4-9803-0800200c9a66",
      "apiUrl": "http://api.ft.com/brands/89d15f70-640d-11e4-9803-0800200c9a66",
      "types": [
        "http://www.ft.com/ontology/core/Thing",
        "http://www.ft.com/ontology/concept/Concept",
        "http://www.ft.com/ontology/classification/Classification",
        "http://www.ft.com/ontology/product/Brand"
      ],
      "prefLabel": "FT Alphaville",
      "type": "BRAND",
      "directType": "http://www.ft.com/ontology/product/Brand",
      "url": "https://www.ft.com/stream/89d15f70-640d-11e4-9803-0800200c9a66",
      "relativeUrl": "/stream/89d15f70-640d-11e4-9803-0800200c9a66",
      "preposition": "from"
    },
    {
      "predicate": "http://www.ft.com/ontology/classification/isPrimarilyClassifiedBy",
      "id": "c91b1fad-1097-468b-be82-9a8ff717d54c",
      "apiUrl": "http://api.ft.com/things/c91b1fad-1097-468b-be82-9a8ff717d54c",
      "types": [
        "http://www.ft.com/ontology/core/Thing",
        "http://www.ft.com/ontology/concept/Concept",
        "http://www.ft.com/ontology/Topic"
      ],
      "prefLabel": "Markets",
      "type": "TOPIC",
      "directType": "http://www.ft.com/ontology/Topic",
      "url": "https://www.ft.com/markets",
      "preposition": "on",
      "relativeUrl": "/markets"
    }
  ],
  "brandConcept": {
    "predicate": "http://www.ft.com/ontology/classification/isClassifiedBy",
    "id": "89d15f70-640d-11e4-9803-0800200c9a66",
    "apiUrl": "http://api.ft.com/brands/89d15f70-640d-11e4-9803-0800200c9a66",
    "types": [
      "http://www.ft.com/ontology/core/Thing",
      "http://www.ft.com/ontology/concept/Concept",
      "http://www.ft.com/ontology/classification/Classification",
      "http://www.ft.com/ontology/product/Brand"
    ],
    "prefLabel": "FT Alphaville",
    "type": "BRAND",
    "directType": "http://www.ft.com/ontology/product/Brand",
    "url": "https://www.ft.com/stream/89d15f70-640d-11e4-9803-0800200c9a66",
    "relativeUrl": "/stream/89d15f70-640d-11e4-9803-0800200c9a66",
    "preposition": "from"
  },
  "authorConcepts": [],
  "design": {
    "theme": "basic",
    "layout": "default"
  },
  "displayConcept": {
    "predicate": "http://www.ft.com/ontology/classification/isPrimarilyClassifiedBy",
    "id": "c91b1fad-1097-468b-be82-9a8ff717d54c",
    "apiUrl": "http://api.ft.com/things/c91b1fad-1097-468b-be82-9a8ff717d54c",
    "types": [
      "http://www.ft.com/ontology/core/Thing",
      "http://www.ft.com/ontology/concept/Concept",
      "http://www.ft.com/ontology/Topic"
    ],
    "prefLabel": "Markets",
    "type": "TOPIC",
    "directType": "http://www.ft.com/ontology/Topic",
    "url": "https://www.ft.com/markets",
    "preposition": "on",
    "relativeUrl": "/markets",
    "isDisplayTag": false
  },
  "teaser": {
    "id": "d75632d9-e62e-37bb-aa73-22a8cf60aaac",
    "url": "http://ftalphaville.ft.com/marketslive/2019-02-14/",
    "relativeUrl": "http://ftalphaville.ft.com/marketslive/2019-02-14/",
    "type": "article",
    "indicators": {
      "isColumn": false,
      "isOpinion": false,
      "isScoop": false,
      "isExclusive": false,
      "isEditorsChoice": false,
      "accessLevel": "registered"
    },
    "metaPrefixText": null,
    "metaSuffixText": null,
    "metaLink": {
      "predicate": "http://www.ft.com/ontology/classification/isPrimarilyClassifiedBy",
      "id": "c91b1fad-1097-468b-be82-9a8ff717d54c",
      "prefLabel": "Markets",
      "type": "TOPIC",
      "url": "https://www.ft.com/markets",
      "relativeUrl": "/markets"
    },
    "metaAltLink": null,
    "title": "Markets Live: Thursday, 14th February 2019",
    "altStandfirst": null,
    "publishedDate": "2019-02-14T11:10:19.000Z",
    "firstPublishedDate": "2019-02-14T11:10:19.000Z",
    "image": {},
    "headshot": null,
    "parentTheme": null
  },
  "contentStats": {
    "wordCount": 1,
    "paragraphs": 0,
    "relatedBoxes": 0,
    "pullQuotes": 0,
    "pullQuotesWithImages": 0,
    "bigNumbers": 0,
    "images": 0,
    "responsiveImages": 0,
    "graphics": 0,
    "audio": 0,
    "videos": 0,
    "internalVideos": 0,
    "externalVideos": 0,
    "subheadings": 0,
    "curatedRecommended": 0,
    "layouts": 0,
    "layoutSlots": 0,
    "infoBox": 0,
    "tables": 0,
    "timelines": 0,
    "singleArticleRecommendations": 0,
    "sentiment": 0,
    "scoreGraphicVolume": 0,
    "scoreGraphicDensity": 0,
    "scorePictureVolume": 0,
    "scorePictureDensity": 0
  },
  "isMarketsLive": true,
  "av2WebUrl": "/marketslive/2019-02-14/",
  "bodyHTML": "<div class=\"webchat-closed-content\"><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:10:38.000Z\" title=\"Thu Feb 14 2019 11:10:38 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:10:38 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:10 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550142653\" data-mid=\"1436474\" data-rawmessage=\"Hello, yes, hi, I&apos;m here.\" id=\"webchat-msg-1436474\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:10am</span></span><div class=\"messagebody\"><p>Hello, yes, hi, I&apos;m here.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550142663\" data-mid=\"1436475\" data-rawmessage=\"/And so&apos;s everyone else./\" id=\"webchat-msg-1436475\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:11am</span></span><div class=\"messagebody\"><p><em>And so&apos;s everyone else.</em></p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Blank canvas</span>\n\t\t\t\t\t\t\t\tYay!!  Markets Live is alive\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550142697\" data-mid=\"1436477\" data-rawmessage=\"Honestly, some of the emails doing the rounds at the moment. Sheesh.\" id=\"webchat-msg-1436477\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:11am</span></span><div class=\"messagebody\"><p>Honestly, some of the emails doing the rounds at the moment. Sheesh.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Blank canvas</span>\n\t\t\t\t\t\t\t\tWhere is everyone?\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:11:48.000Z\" title=\"Thu Feb 14 2019 11:11:48 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:11:48 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:11 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550142723\" data-mid=\"1436478\" data-rawmessage=\"Though I guess they&apos;re no worse than some of the stories printed in supposedly legitimate newspapers.\" id=\"webchat-msg-1436478\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:12am</span></span><div class=\"messagebody\"><p>Though I guess they&apos;re no worse than some of the stories printed in supposedly legitimate newspapers.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tBonjour\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Marcus</span>\n\t\t\t\t\t\t\t\tGive us a clue!What did the emails say?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">GBKrona</span>\n\t\t\t\t\t\t\t\tJambo\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">PBateman</span>\n\t\t\t\t\t\t\t\tMorning\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">1st Lt. Fletcher Christian</span>\n\t\t\t\t\t\t\t\tMorning\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tBreaking news: Emails rumor that Bryce occasionally smiles. Rumors totally denied. (Ok I am being light hearted and retract that rumor).\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550142846\" data-mid=\"1436480\" data-rawmessage=\"It makes you despair. Or would, if you didn&apos;t have a natural aversion to getting embroiled in pig wrestling.\" id=\"webchat-msg-1436480\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:14am</span></span><div class=\"messagebody\"><p>It makes you despair. Or would, if you didn&apos;t have a natural aversion to getting embroiled in pig wrestling.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">J L</span>\n\t\t\t\t\t\t\t\tGood Morning.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tIs that even legal?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Manxish</span>\n\t\t\t\t\t\t\t\tHello all\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550142916\" data-mid=\"1436481\" data-rawmessage=\"As in ....\" id=\"webchat-msg-1436481\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:15am</span></span><div class=\"messagebody\"><p>As in ....</p>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:15:04.000Z\" title=\"Thu Feb 14 2019 11:15:04 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:15:04 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:15 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550142919\" data-mid=\"1436482\" data-rawmessage=\"https://i.imgur.com/X4rDec0.png\" id=\"webchat-msg-1436482\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:15am</span></span><div class=\"messagebody\"><p><img class=\"picture\" src=\"https://www.ft.com/__origami/service/image/v2/images/raw/%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fi.imgur.com%252FX4rDec0.png%3Fsource%3DAlphaville%26width%3D675%26fit%3Dscale-down?source=Alphaville\"></p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\t@Soundbuy - u mean pig wrestling?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tAye......\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">GBKrona</span>\n\t\t\t\t\t\t\t\tPig wrestling - only for Cameron &amp; BoJo types...  Lets stick to our game\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550142960\" data-mid=\"1436483\" data-rawmessage=\"So anyway, there&apos;s nothing in any of it. Literally nothing. You can all stop pinging me now. Ta.\" id=\"webchat-msg-1436483\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:16am</span></span><div class=\"messagebody\"><p>So anyway, there&apos;s nothing in any of it. Literally nothing. You can all stop pinging me now. Ta.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tDidn&apos;t Elvis like watching wrestling??\n\t\t\t\t\t\t\t</div><div class=\"msg separator has-headshot\" data-timestamp=\"1550142964\" data-mid=\"1436484\" data-rawmessage=\"11:15AM\" id=\"webchat-msg-1436484\">\n\t<div class=\"messagebody\"><time class=\"o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:16:04.000Z\" title=\"Thu Feb 14 2019 11:16:04 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:16:04 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\tundefined\n\t\t\t\t\t\t\t\t</time></div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tNothing in what ....... we all wonder...........\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:16:31.000Z\" title=\"Thu Feb 14 2019 11:16:31 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:16:31 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:16 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143006\" data-mid=\"1436485\" data-rawmessage=\"And so to results. There&apos;s lots.\" id=\"webchat-msg-1436485\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:16am</span></span><div class=\"messagebody\"><p>And so to results. There&apos;s lots.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Lemmy</span>\n\t\t\t\t\t\t\t\tAll very cryptic\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143042\" data-mid=\"1436486\" data-rawmessage=\"And I think, sticking with the theme, we should start with colostomy bags.\" id=\"webchat-msg-1436486\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:17am</span></span><div class=\"messagebody\"><p>And I think, sticking with the theme, we should start with colostomy bags.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Blank canvas</span>\n\t\t\t\t\t\t\t\tI thought GBShaw was a vegetarian\n\t\t\t\t\t\t\t</div><div class=\"msg price has-headshot\" data-timestamp=\"1550143053\" data-mid=\"1436487\" data-rawmessage=\"&lt;strong&gt;ConvaTec Group PLC (CTEC:LSE):&lt;/strong&gt; Last: 120.70, down 27.55 (-18.58%), High: 128.15, Low: 113.25, Volume: 8.24m\" id=\"webchat-msg-1436487\">\n\t<div class=\"messagebody\"><strong>ConvaTec Group PLC (CTEC:LSE):</strong> Last: 120.70, down 27.55 (-18.58%), High: 128.15, Low: 113.25, Volume: 8.24m</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Super SWF</span>\n\t\t\t\t\t\t\t\tWhat no pig wrestling?  OK colostomy bags will do.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\tAnyone read this?https://www.theguardian.com/uk-news/2019/feb/13/garden-bridge-charity-spent-535m-with-no-construction-tfl-finds\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\t@Lemmy - agree. So pigs are mentioned - so obvious reference is Cameron. So implies politics and prime minster. So is it to do with the PM and Brexit?\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:18:42.000Z\" title=\"Thu Feb 14 2019 11:18:42 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:18:42 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:18 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143137\" data-mid=\"1436488\" data-rawmessage=\"Demand isn&apos;t what it should be for things that are full of s__t. Maybe someone should tell the foreign press corps.\" id=\"webchat-msg-1436488\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:18am</span></span><div class=\"messagebody\"><p>Demand isn&apos;t what it should be for things that are full of s__t. Maybe someone should tell the foreign press corps.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">DJ</span>\n\t\t\t\t\t\t\t\tmorning all\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tAnd Boris bridge in the news. So Bojo ambitions for PM? Has he been caught doing something?\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143159\" data-mid=\"1436489\" data-rawmessage=\"The gist here is that Convatec was massively underinvested when it floated.\" id=\"webchat-msg-1436489\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:19am</span></span><div class=\"messagebody\"><p>The gist here is that Convatec was massively underinvested when it floated.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\t@waynej - caught wasting taxpayers money, again.............\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143181\" data-mid=\"1436490\" data-rawmessage=\"And was carrying debt not shy of 3x EBITDA.\" id=\"webchat-msg-1436490\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:19am</span></span><div class=\"messagebody\"><p>And was carrying debt not shy of 3x EBITDA.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tBottom dropped out of the market?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\tMorning all.\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:20:28.000Z\" title=\"Thu Feb 14 2019 11:20:28 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:20:28 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:20 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143243\" data-mid=\"1436491\" data-rawmessage=\"And since then, Coloplast -- the company that Convatec&apos;s float was benchmarked against -- has far outperformed.\" id=\"webchat-msg-1436491\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:20am</span></span><div class=\"messagebody\"><p>And since then, Coloplast -- the company that Convatec&apos;s float was benchmarked against -- has far outperformed.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143266\" data-mid=\"1436492\" data-rawmessage=\"So Convatec has, after several profit warnings, said it&apos;ll fix things.\" id=\"webchat-msg-1436492\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:21am</span></span><div class=\"messagebody\"><p>So Convatec has, after several profit warnings, said it&apos;ll fix things.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143276\" data-mid=\"1436493\" data-rawmessage=\"But it&apos;ll take three years of investment.\" id=\"webchat-msg-1436493\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:21am</span></span><div class=\"messagebody\"><p>But it&apos;ll take three years of investment.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@BornCynic: amazing, isn&apos;t it, how a privately funded initiative (wasn&apos;t it?) managed to squander public money.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\tWhat is it with London and Mayors? Livinstone, Boris, and now Sadiq Khan. Speaking as a non-Londoner, I suspect you deserve them.\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:21:33.000Z\" title=\"Thu Feb 14 2019 11:21:33 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:21:33 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:21 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143308\" data-mid=\"1436494\" data-rawmessage=\"So 2019 EBITDA steps down by 10%-ish. Future years by up to 20%ish.\" id=\"webchat-msg-1436494\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:21am</span></span><div class=\"messagebody\"><p>So 2019 EBITDA steps down by 10%-ish. Future years by up to 20%ish.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\tThe bill for his vanity projects so far is about &#xA3;940 million according to the Guardian. I&apos;m going to write to him with an idea and offer my services as a consultant. I suggest that we all do. Beats this investing game.\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143338\" data-mid=\"1436495\" data-rawmessage=\"Oh, bear in mind Convatec still doesn&apos;t have a CEO.\" id=\"webchat-msg-1436495\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:22am</span></span><div class=\"messagebody\"><p>Oh, bear in mind Convatec still doesn&apos;t have a CEO.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143358\" data-mid=\"1436496\" data-rawmessage=\"Here&apos;s Morgan Stanley.\" id=\"webchat-msg-1436496\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:22am</span></span><div class=\"messagebody\"><p>Here&apos;s Morgan Stanley.</p>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:22:48.000Z\" title=\"Thu Feb 14 2019 11:22:48 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:22:48 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:22 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143383\" data-mid=\"1436497\" data-rawmessage=\"CTEC reported its 2H FY18 result this morning, which was pretty close to\nconsensus on both organic sales growth and EBIT (before non-recurring items) but FY19E guidance fell well below expectations. Q4 FY18A organic sales growth came in at -4% vs. consensus of -3.5% but in line with our thinking. 2H FY18A EBIT came in at $226mn vs. consensus of $227mn, with an EBIT margin of 24.8% vs. consensus of 24.5%. More relevant to the share price today is FY19E guidance, which if using the mid point of the adjusted margin guidance range, would equate to a -7-8% downgrade to adjusted EBIT. The consensus earnings downgrade to Net Income would likely be higher, given that the company carries high leverage with a Net Debt / EBITDA of ~3x. A key debate for the analyst call today, is what should actually be excluded in the adjusted EBIT margin, which is guided to 21-22.5% (excluding transformation initiatives and costs related to medical device regulations) vs. 18-20% including these items. A further consideration for the share price over the short to medium-term is how reliable the company&apos;s refreshed execution model &quot;Pivot to Growth&quot; will be perceived by investors, with the company yet to appoint a new CEO.\" id=\"webchat-msg-1436497\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:23am</span></span><div class=\"messagebody\"><blockquote><p>CTEC reported its 2H FY18 result this morning, which was pretty close to<br>\nconsensus on both organic sales growth and EBIT (before non-recurring items) but FY19E guidance fell well below expectations. Q4 FY18A organic sales growth came in at -4% vs. consensus of -3.5% but in line with our thinking. 2H FY18A EBIT came in at $226mn vs. consensus of $227mn, with an EBIT margin of 24.8% vs. consensus of 24.5%. More relevant to the share price today is FY19E guidance, which if using the mid point of the adjusted margin guidance range, would equate to a -7-8% downgrade to adjusted EBIT. The consensus earnings downgrade to Net Income would likely be higher, given that the company carries high leverage with a Net Debt / EBITDA of ~3x. A key debate for the analyst call today, is what should actually be excluded in the adjusted EBIT margin, which is guided to 21-22.5% (excluding transformation initiatives and costs related to medical device regulations) vs. 18-20% including these items. A further consideration for the share price over the short to medium-term is how reliable the company&apos;s refreshed execution model &quot;Pivot to Growth&quot; will be perceived by investors, with the company yet to appoint a new CEO.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\tOn another note -- have you read the marxists in China story?\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143407\" data-mid=\"1436498\" data-rawmessage=\"And Cazenove.\" id=\"webchat-msg-1436498\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:23am</span></span><div class=\"messagebody\"><p>And Cazenove.</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143422\" data-mid=\"1436499\" data-rawmessage=\"Q4 sales missed by 2.6% on an absolute basis, with weakness in the two main division (Woundcare, -4.1% vs. cons; and, Ostomy, -3.1%). In Woundcare (-1.8% organic growth vs. +0.6% cons), negative channel inventory movements in the UK impacted sales and US performance continues to be poor (contrast to Smith &amp; Nephew growing their US Wound business double-digit in H2 and strong performance by Molnlycke). Ostomy (-1.5% organic vs. -0.3% cons) continued to be poor, with the supply issues continuing to drag on US growth. Continence Care was a bright spot (3.9% organic vs. 3.2% cons) driven by good performance in HDG. Infusion Devices saw lower sales on destocking at a key customer (as previously warned).\" id=\"webchat-msg-1436499\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:23am</span></span><div class=\"messagebody\"><blockquote><p>Q4 sales missed by 2.6% on an absolute basis, with weakness in the two main division (Woundcare, -4.1% vs. cons; and, Ostomy, -3.1%). In Woundcare (-1.8% organic growth vs. +0.6% cons), negative channel inventory movements in the UK impacted sales and US performance continues to be poor (contrast to Smith &amp; Nephew growing their US Wound business double-digit in H2 and strong performance by Molnlycke). Ostomy (-1.5% organic vs. -0.3% cons) continued to be poor, with the supply issues continuing to drag on US growth. Continence Care was a bright spot (3.9% organic vs. 3.2% cons) driven by good performance in HDG. Infusion Devices saw lower sales on destocking at a key customer (as previously warned).</p></blockquote>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:24:12.000Z\" title=\"Thu Feb 14 2019 11:24:12 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:24:12 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:24 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143467\" data-mid=\"1436500\" data-rawmessage=\"The company has guided to 2019 organic growth of 1.0-2.5% [cons: 2.4%] and Adjusted EBIT margin of 21.0-22.5% [when one excludes $50m associated with EU MDR and the transformation program], consensus is currently looking for Adjusted EBIT margins of 22.9%. Taking the new base and the middle of the range [as well as a ~2% FX revenue headwind], implies ~7% cuts to Adjusted EBIT in 2019.\" id=\"webchat-msg-1436500\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:24am</span></span><div class=\"messagebody\"><blockquote><p>The company has guided to 2019 organic growth of 1.0-2.5% [cons: 2.4%] and Adjusted EBIT margin of 21.0-22.5% [when one excludes $50m associated with EU MDR and the transformation program], consensus is currently looking for Adjusted EBIT margins of 22.9%. Taking the new base and the middle of the range [as well as a ~2% FX revenue headwind], implies ~7% cuts to Adjusted EBIT in 2019.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tI like the &#xA3;2,200 someone paid for breakfast on the Boris bridge\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143488\" data-mid=\"1436501\" data-rawmessage=\"Caz also noted the Coloplast numbers.\" id=\"webchat-msg-1436501\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:24am</span></span><div class=\"messagebody\"><p>Caz also noted the Coloplast numbers.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143515\" data-mid=\"1436502\" data-rawmessage=\"... which were out last week.\" id=\"webchat-msg-1436502\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:25am</span></span><div class=\"messagebody\"><p>... which were out last week.</p>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:25:04.000Z\" title=\"Thu Feb 14 2019 11:25:04 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:25:04 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:25 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143519\" data-mid=\"1436503\" data-rawmessage=\"8% organic growth in Ostomy Care and Continence Care, and 10% in Wound Care (on soft comps) although management noted good performance in the UK and France. Coloplast has grown well ahead of ConvaTec, and has not historically been a good indicator of ConvaTec performance. Molnlycke (part of Investor AB) a major competitor in wound care (we estimate ~10% market share), reported Q4 results on 24 January with 8 growth in their Wound Care division. Molnlycke management noted that they had seen strongest growth in Emerging Markets &#x201C;But we also see a very good growth in the U.S. in this quarter&#x2026; Europe actually also showed a quite solid performance. Europe was good. The weakest area in Europe remains UK, but we had a solid growth also in Europe in the quarter. Profitability was down somewhat compared to last year, but that is mainly related to that we are puting a lot of efforts behind sales and marketing out to push these new products out to the market.&#x201D;\" id=\"webchat-msg-1436503\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:25am</span></span><div class=\"messagebody\"><blockquote><p>8% organic growth in Ostomy Care and Continence Care, and 10% in Wound Care (on soft comps) although management noted good performance in the UK and France. Coloplast has grown well ahead of ConvaTec, and has not historically been a good indicator of ConvaTec performance. Molnlycke (part of Investor AB) a major competitor in wound care (we estimate ~10% market share), reported Q4 results on 24 January with 8 growth in their Wound Care division. Molnlycke management noted that they had seen strongest growth in Emerging Markets &#x201C;But we also see a very good growth in the U.S. in this quarter&#x2026; Europe actually also showed a quite solid performance. Europe was good. The weakest area in Europe remains UK, but we had a solid growth also in Europe in the quarter. Profitability was down somewhat compared to last year, but that is mainly related to that we are puting a lot of efforts behind sales and marketing out to push these new products out to the market.&#x201D;</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\t@waynej - yes, you do not need a good lawyer to get your money back on that one.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">red</span>\n\t\t\t\t\t\t\t\tazn? after early indifference mkt seems to like...nice rally since open. best performing of the high yielders\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">goldenoldie</span>\n\t\t\t\t\t\t\t\thello all,  any ideas how i may invest in uk shares in canabis please\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143595\" data-mid=\"1436504\" data-rawmessage=\"A reminder that Nordic Capital and Avista Capital Partners floated Convatec in 2016.\" id=\"webchat-msg-1436504\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:26am</span></span><div class=\"messagebody\"><p>A reminder that Nordic Capital and Avista Capital Partners floated Convatec in 2016.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143620\" data-mid=\"1436505\" data-rawmessage=\"And a habitual reminder that, if PE&apos;s selling, you probably want to be a bit wary about buying.\" id=\"webchat-msg-1436505\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:27am</span></span><div class=\"messagebody\"><p>And a habitual reminder that, if PE&apos;s selling, you probably want to be a bit wary about buying.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">hornblower</span>\n\t\t\t\t\t\t\t\tquite something the VEO of Restaurant Group hugely overpays for a stalling business, forces through a heavily dilutive rights issue to pay for it against most shareholders wishes ... then leaves\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:26:51.000Z\" title=\"Thu Feb 14 2019 11:26:51 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:26:51 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:26 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg separator has-headshot\" data-timestamp=\"1550143626\" data-mid=\"1436506\" data-rawmessage=\"11:26AM\" id=\"webchat-msg-1436506\">\n\t<div class=\"messagebody\"><time class=\"o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:27:06.000Z\" title=\"Thu Feb 14 2019 11:27:06 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:27:06 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\tundefined\n\t\t\t\t\t\t\t\t</time></div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">hornblower</span>\n\t\t\t\t\t\t\t\t*CEO\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143655\" data-mid=\"1436507\" data-rawmessage=\"(@goldenoldie: no, but there&apos;s a guy in my local playpark who can set you up.)\" id=\"webchat-msg-1436507\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:27am</span></span><div class=\"messagebody\"><p>(@goldenoldie: no, but there&apos;s a guy in my local playpark who can set you up.)</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@goldenoldie is it even legal? You could shop them to HMRC for a cut of the take, I suppose.\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143693\" data-mid=\"1436508\" data-rawmessage=\"Stick to results for a moment. AstraZeneca mentioned.\" id=\"webchat-msg-1436508\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:28am</span></span><div class=\"messagebody\"><p>Stick to results for a moment. AstraZeneca mentioned.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">cheeckychappy</span>\n\t\t\t\t\t\t\t\t@BE - fyi there is a rave up coming up in one of your local coffee shops.\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:28:06.000Z\" title=\"Thu Feb 14 2019 11:28:06 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:28:06 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:28 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg price has-headshot\" data-timestamp=\"1550143701\" data-mid=\"1436509\" data-rawmessage=\"&lt;strong&gt;AstraZeneca PLC (AZN:LSE):&lt;/strong&gt; Last: 6,052, up 331 (+5.79%), High: 6,056, Low: 5,847, Volume: 968.72k\" id=\"webchat-msg-1436509\">\n\t<div class=\"messagebody\"><strong>AstraZeneca PLC (AZN:LSE):</strong> Last: 6,052, up 331 (+5.79%), High: 6,056, Low: 5,847, Volume: 968.72k</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tHe was pretty loved - recall Sohn preso from AB on Restaurant Group was all about McCue @hornblower\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">PBateman</span>\n\t\t\t\t\t\t\t\tMight be a bit early but I&apos;d appreciate it if there&apos;s anything out on MoneySuperMarket.com\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">cheeckychappy</span>\n\t\t\t\t\t\t\t\t@BE - in the den of Harles\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143775\" data-mid=\"1436510\" data-rawmessage=\"(@cheeckychappy: loop me in. Given it&apos;s 30 seconds from my door, rude not to drop by.)\" id=\"webchat-msg-1436510\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:29am</span></span><div class=\"messagebody\"><p>(@cheeckychappy: loop me in. Given it&apos;s 30 seconds from my door, rude not to drop by.)</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Patience</span>\n\t\t\t\t\t\t\t\t@A.M. - there is a shop selling Cannabidiol vaping fluid in my part of Norwich.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">goldenoldie</span>\n\t\t\t\t\t\t\t\tthanks b e  :-)))\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">GBKrona</span>\n\t\t\t\t\t\t\t\tAZN very impressive. Think GSK is trying to emulate this with recent oncology push, bt perhaps too little too late into oncology game?\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143815\" data-mid=\"1436511\" data-rawmessage=\"So at the headline level, EPS of $3.46 is vs a $3.35 consensus.\" id=\"webchat-msg-1436511\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:30am</span></span><div class=\"messagebody\"><p>So at the headline level, EPS of $3.46 is vs a $3.35 consensus.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Patience: I stand corrected, then.\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:30:40.000Z\" title=\"Thu Feb 14 2019 11:30:40 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:30:40 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:30 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143855\" data-mid=\"1436512\" data-rawmessage=\"And unexpectedly for AstraZeneca, it&apos;s on sales.\" id=\"webchat-msg-1436512\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:30am</span></span><div class=\"messagebody\"><p>And unexpectedly for AstraZeneca, it&apos;s on sales.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143876\" data-mid=\"1436513\" data-rawmessage=\"You also have an implied 2% guide upwards in the 2019 outlook.\" id=\"webchat-msg-1436513\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:31am</span></span><div class=\"messagebody\"><p>You also have an implied 2% guide upwards in the 2019 outlook.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143905\" data-mid=\"1436514\" data-rawmessage=\"Now, none of this really affects the main concerns with AstraZeneca .....\" id=\"webchat-msg-1436514\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:31am</span></span><div class=\"messagebody\"><p>Now, none of this really affects the main concerns with AstraZeneca .....</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\tPatesserie Valerie saved?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tThe issue with both GSK and AZN is how covered is the dividend and what is the risk of a reset one day\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:31:51.000Z\" title=\"Thu Feb 14 2019 11:31:51 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:31:51 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:31 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550143926\" data-mid=\"1436515\" data-rawmessage=\"......... which is that it&apos;s holing out the business with an externalisation strategy.\" id=\"webchat-msg-1436515\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:32am</span></span><div class=\"messagebody\"><p>......... which is that it&apos;s holing out the business with an externalisation strategy.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">goldenoldie</span>\n\t\t\t\t\t\t\t\tcan invest in usa/canada  but easier to invest u/k\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550143971\" data-mid=\"1436516\" data-rawmessage=\"But if you&apos;re of a mind that selling drugs is what drug companies should do, they&apos;re reassuring numbers. Here&apos;s Barclays.\" id=\"webchat-msg-1436516\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:32am</span></span><div class=\"messagebody\"><p>But if you&apos;re of a mind that selling drugs is what drug companies should do, they&apos;re reassuring numbers. Here&apos;s Barclays.</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143982\" data-mid=\"1436517\" data-rawmessage=\"Q4 sales are 2% ahead of cons (1% vs BARC) on products with externalisation in-line but higher costs (partly COGS, mostly SG&amp;A) driving a 10% core EBITA miss (-7% vs BARC). That was offset by below the line items (lower financials and a big beat on tax) to drive core EPS 7% ahead of both cons/BARC. FY19 guidance of HSD product sales growth and core EPS of 3.50-3.70 plus a LSD FX headwind on both sales/EPS is slightly ahead of consensus with+7% (BARC +9%) and 3.49 (BARC $3.80) respectively. Perhaps more importantly there is guidance of mid-teens core EBITA growth vs cons +3% and BARC +10%; whilst it is hard to ascertain the extent to which externalisation/OOI is driving that (the only guidance is for a &#x201C;decline&#x201D; vs cons -11%/-38% on both items respectively&#x2026;) we nonetheless think that should reassure and note that is far closer to our expectation than consensus (the offset on core EPS is higher tax for FY19 which is guided at 18-22% vs cons at 17%). The H2 divi is $1.90 giving an FY18 flat $2.80 divi as expected; CFO / FCF came in at $2.6bn (down yoy mostly on working capital/legal provisions) and $1.6bn respectively, which are very disappointing vs BARC at $5.4bn and $3.5bn respectively.\" id=\"webchat-msg-1436517\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:33am</span></span><div class=\"messagebody\"><blockquote><p>Q4 sales are 2% ahead of cons (1% vs BARC) on products with externalisation in-line but higher costs (partly COGS, mostly SG&amp;A) driving a 10% core EBITA miss (-7% vs BARC). That was offset by below the line items (lower financials and a big beat on tax) to drive core EPS 7% ahead of both cons/BARC. FY19 guidance of HSD product sales growth and core EPS of 3.50-3.70 plus a LSD FX headwind on both sales/EPS is slightly ahead of consensus with+7% (BARC +9%) and 3.49 (BARC $3.80) respectively. Perhaps more importantly there is guidance of mid-teens core EBITA growth vs cons +3% and BARC +10%; whilst it is hard to ascertain the extent to which externalisation/OOI is driving that (the only guidance is for a &#x201C;decline&#x201D; vs cons -11%<em>-38% on both items respectively&#x2026;) we nonetheless think that should reassure and note that is far closer to our expectation than consensus (the offset on core EPS is higher tax for FY19 which is guided at 18-22% vs cons at 17%). The H2 divi is $1.90 giving an FY18 flat $2.80 divi as expected; CFO </em> FCF came in at $2.6bn (down yoy mostly on working capital/legal provisions) and $1.6bn respectively, which are very disappointing vs BARC at $5.4bn and $3.5bn respectively.</p></blockquote>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:33:00.000Z\" title=\"Thu Feb 14 2019 11:33:00 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:33:00 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:33 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550143995\" data-mid=\"1436518\" data-rawmessage=\"In terms of products the mix is solid, with Tagrisso, Imfinzi and Lynparza all delivering strong HSD beats, as did Brilinta and Fasenra (14% beat for latter). Farxiga and Calquence were broadly in-line whilst less positive were misses for much of respiratory (excl Pulmicort) and Bydureon (manufacturing issues cited for the latter but unquantified). Regionally China remained stellar albeit with a slight slowdown in Q4 (+22% CER), offset by a better Q4 for the rest of EM (+10%). On the R&amp;D side there is surprising news that Fasenra subcut has been filed; KESTREL and roxa MACE remain on track for H1 readout along with POLO, whilst NEPTUNE/POSEIDON will be &#x201C;refined&#x201D; following MYSTIC along with a number of new IO trials announced. Lokelma US launch is confirmed for H219.\" id=\"webchat-msg-1436518\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:33am</span></span><div class=\"messagebody\"><blockquote><p>In terms of products the mix is solid, with Tagrisso, Imfinzi and Lynparza all delivering strong HSD beats, as did Brilinta and Fasenra (14% beat for latter). Farxiga and Calquence were broadly in-line whilst less positive were misses for much of respiratory (excl Pulmicort) and Bydureon (manufacturing issues cited for the latter but unquantified). Regionally China remained stellar albeit with a slight slowdown in Q4 (+22% CER), offset by a better Q4 for the rest of EM (+10%). On the R&amp;D side there is surprising news that Fasenra subcut has been filed; KESTREL and roxa MACE remain on track for H1 readout along with POLO, whilst NEPTUNE/POSEIDON will be &#x201C;refined&#x201D; following MYSTIC along with a number of new IO trials announced. Lokelma US launch is confirmed for H219.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tThat UK IPO index Bloomberg runs must be looking interesting...\n\t\t\t\t\t\t\t</div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550144008\" data-mid=\"1436519\" data-rawmessage=\"2019 guidance is for HSD product sales growth (+ a FX LSD adverse impact) is in-line with Barclays/consensus at +10%/+7% with the core EPS bracket of $3.50-3.70 + LSD adverse FX impact above consensus at $3.46 but trailing our $3.91 FX-adj forecast. AZN has reiterated a projected unquantified decline in the sum of externalisation revenues (Barclays/consensus has -15%/-12%) and Core OOI (Barclays/consensus at -24%/-40%) alongside guidance for a LSD increase in Core Operating Expenses (Barclays/consensus at +8%/+7%) and mid-teens growth for Core Operating Profit (Barclays/consensus at +11%/+3%). Other guidance items include Core Tax Rate of 18-22%, capex being broadly stable and restructuring expenses reducing vs FY18, with Barclays estimates at 19% core tax rate and capex declining by 7%.\" id=\"webchat-msg-1436519\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:33am</span></span><div class=\"messagebody\"><blockquote><p>2019 guidance is for HSD product sales growth (+ a FX LSD adverse impact) is in-line with Barclays/consensus at +10%/+7% with the core EPS bracket of $3.50-3.70 + LSD adverse FX impact above consensus at $3.46 but trailing our $3.91 FX-adj forecast. AZN has reiterated a projected unquantified decline in the sum of externalisation revenues (Barclays/consensus has -15%/-12%) and Core OOI (Barclays/consensus at -24%/-40%) alongside guidance for a LSD increase in Core Operating Expenses (Barclays/consensus at +8%/+7%) and mid-teens growth for Core Operating Profit (Barclays/consensus at +11%/+3%). Other guidance items include Core Tax Rate of 18-22%, capex being broadly stable and restructuring expenses reducing vs FY18, with Barclays estimates at 19% core tax rate and capex declining by 7%.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\t@borncynic  what exactly did the contractors do for that money would have been a very expensive site survey even allowing for the fact that some of it was underwater\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">SoS</span>\n\t\t\t\t\t\t\t\tMcCue leaving has sure hit the price. @Juliogelsias\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\tCommerzbank has learnt a lesson, it is hiring Full time employees and ditching outsourced IT re Stephen Engels on Bloomberg radio interview\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tISn&apos;t the issue with AZN&apos;s hollowing out strategy also related to how everything is accounted?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tGood mid-morning capitalists\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\t@FATDAZ - apologies, no idea. Whatever they did it was a bit of a waste of time?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\tMorning all by the way\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144163\" data-mid=\"1436520\" data-rawmessage=\"Hey, anyone been keeping an eye on drug trial results this week? Nektar, Orion, Gilead all with notable and unexpected failures from the oncology pipeline.\" id=\"webchat-msg-1436520\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:36am</span></span><div class=\"messagebody\"><p>Hey, anyone been keeping an eye on drug trial results this week? Nektar, Orion, Gilead all with notable and unexpected failures from the oncology pipeline.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tReasonable people have asked reasonable questions about the differences between outlicensing / royalties / milestones across pharma cos and what is booked where and how minorities are treated etc.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\t@Borncynic no need to apologise, but the whole thing leaves a bad  taste in the mouth\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tGilead - was NASH rather than onco IIRC?\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:37:14.000Z\" title=\"Thu Feb 14 2019 11:37:14 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:37:14 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:37 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550144249\" data-mid=\"1436521\" data-rawmessage=\"Still, I&apos;m sure all the other immuno-oncology drugs getting priced in SOTP models as 2025 blockbusters won&apos;t disappoint too.\" id=\"webchat-msg-1436521\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:37am</span></span><div class=\"messagebody\"><p>Still, I&apos;m sure all the other immuno-oncology drugs getting priced in SOTP models as 2025 blockbusters won&apos;t disappoint too.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\t@SoS &#xA3;100m worth...all the studies always point to far too much emphasis put on key person effects\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">goldenoldie</span>\n\t\t\t\t\t\t\t\tSativa Investments ..any comment/advice please\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">hornblower</span>\n\t\t\t\t\t\t\t\tGilead - Handmaids Tale\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tThe Daily Mail today was saying that Vertex is reopening talks with the NHS about its cystic fibrosis drugs.  Vertex is odd - it&apos;s basically doing exactly what we complain about Big Pharma not doing, spending immensely on research, it&apos;s just that &apos;immensely&apos; turns out to be rather a big number\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\talso re the garden bridge  how does a civil engineering feasibility study/ project become a charity? and why ?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tcuring cystic fibrosis in most patients, yay!  But for &#xA3;600 a day\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144316\" data-mid=\"1436522\" data-rawmessage=\"(@Wayne -- ah yes, it was. Apologies to them, and you.)\" id=\"webchat-msg-1436522\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:38am</span></span><div class=\"messagebody\"><p>(@Wayne -- ah yes, it was. Apologies to them, and you.)</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550144354\" data-mid=\"1436523\" data-rawmessage=\"We remain ruthlessly focused on the in-market and future\nperformance of Lynparza, Tagrisso, Infimzi and China as the key determinants of our long held conviction thesis on AZN. The contribution of the maligned externalization revenues is fading and likely convergence with peer definitions of non-Core EPS are likely only 12-24 months away. The long overdue integration of Medimmune inside AZN will likely improve productivity and potentially allow USD300-500m of cost savings or cost avoidance (When Two Comes One?\nMedImmune Head Exits. Remain Buy and here both Jan 2019). On the negative side we monitor carefully competitor activities with 3rd generation EGFR-TKI (JNJ and others). On the positive side, we believe that consensus materially\nunderestimates the revenue potential of Lynparza/ PARP inhibition by perhaps threefold (Lynparza. The Best Is Yet to Come. Reiterating Buy: AZN &amp; MRK Oct 2018). We prefer Buy rated AZN, Sanofi, Bayer and Merck KGaA in EU. MRK is our only Buy rated name among the US majors.\" id=\"webchat-msg-1436523\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:39am</span></span><div class=\"messagebody\"><blockquote><p>We remain ruthlessly focused on the in-market and future<br>\nperformance of Lynparza, Tagrisso, Infimzi and China as the key determinants of our long held conviction thesis on AZN. The contribution of the maligned externalization revenues is fading and likely convergence with peer definitions of non-Core EPS are likely only 12-24 months away. The long overdue integration of Medimmune inside AZN will likely improve productivity and potentially allow USD300-500m of cost savings or cost avoidance (When Two Comes One?<br>\nMedImmune Head Exits. Remain Buy and here both Jan 2019). On the negative side we monitor carefully competitor activities with 3rd generation EGFR-TKI (JNJ and others). On the positive side, we believe that consensus materially<br>\nunderestimates the revenue potential of Lynparza/ PARP inhibition by perhaps threefold (Lynparza. The Best Is Yet to Come. Reiterating Buy: AZN &amp; MRK Oct 2018). We prefer Buy rated AZN, Sanofi, Bayer and Merck KGaA in EU. MRK is our only Buy rated name among the US majors.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t@FATDAZ, isn&apos;t anything associated with Joanna Lumley automatically granted charitable status?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\t@Pharma aah of course :)\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:39:25.000Z\" title=\"Thu Feb 14 2019 11:39:25 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:39:25 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:39 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550144380\" data-mid=\"1436524\" data-rawmessage=\"AZN reported 2% beat on product sales mainly driven by 5% beat\nfor its Oncology franchise. Notable beats include Tagrisso (+5%), Imfinzi (+9%) and Lynparza (+9%) and Onglyza (+10%). We note Tagrisso was held back through China price reductions associated with NDRL entry and subsequent volume enhancement. Importantly China (35% sales) grew 17% in the quarter. Core\noperating income was 10% lower than the street due to higher COGS and higher operating expenses (both SG&amp;A and R&amp;D). Other operating income also missed consensus expectations. However lower net finance costs and taxes during the Q led to 7% beat at EPS. For 2019, AZN expects its topline to grow by high sd at CER. Core EPS guidance is for $3.50-3.70, which at the mid-point reflects c.1% consensus earnings upgrades FX adjusted. Full variance tables are enclosed for products and P&amp;L.\" id=\"webchat-msg-1436524\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:39am</span></span><div class=\"messagebody\"><blockquote><p>AZN reported 2% beat on product sales mainly driven by 5% beat<br>\nfor its Oncology franchise. Notable beats include Tagrisso (+5%), Imfinzi (+9%) and Lynparza (+9%) and Onglyza (+10%). We note Tagrisso was held back through China price reductions associated with NDRL entry and subsequent volume enhancement. Importantly China (35% sales) grew 17% in the quarter. Core<br>\noperating income was 10% lower than the street due to higher COGS and higher operating expenses (both SG&amp;A and R&amp;D). Other operating income also missed consensus expectations. However lower net finance costs and taxes during the Q led to 7% beat at EPS. For 2019, AZN expects its topline to grow by high sd at CER. Core EPS guidance is for $3.50-3.70, which at the mid-point reflects c.1% consensus earnings upgrades FX adjusted. Full variance tables are enclosed for products and P&amp;L.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tit&apos;s a human nature thing to assign success or blame to an individual rather than the system etc...cf Black Box Thinking and blame culture...\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tAnd on numbers it looks like AZN&apos;s ROIC has basically halved over a decade\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tFCF per share had followed\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tPrivate schools and charities.........now there&apos;s a thing......\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\tBank of America Merrill Lynch monthly survey of global fund managers states that emerging markets are now the most crowded trade.\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144458\" data-mid=\"1436525\" data-rawmessage=\"(@Mouselet: &#xA3;600 a day&apos;s an automatic rejection on the QALY, so I doubt talks will take very long.)\" id=\"webchat-msg-1436525\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:40am</span></span><div class=\"messagebody\"><p>(@Mouselet: &#xA3;600 a day&apos;s an automatic rejection on the QALY, so I doubt talks will take very long.)</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\t@BE: USA Retail sales today, any grey?\n\t\t\t\t\t\t\t</div><div class=\"msg separator has-headshot\" data-timestamp=\"1550144472\" data-mid=\"1436526\" data-rawmessage=\"11:40AM\" id=\"webchat-msg-1436526\">\n\t<div class=\"messagebody\"><time class=\"o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:41:12.000Z\" title=\"Thu Feb 14 2019 11:41:12 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:41:12 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\tundefined\n\t\t\t\t\t\t\t\t</time></div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Mouselet: is it a cure, or just a temporary warding-off of the effects?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">red</span>\n\t\t\t\t\t\t\t\tazn will stay around or get bought. in meantime pays out acceptable undemanding divi...in top quarter of ftse divi payers imo.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tAZN: Cashflow from operations has halved or worse; yet dividends have stayed flat to gone up (depending on the exact starting point) over a decade\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tBE: I think Britain offered &#xA3;10,000/yr/patient and Vertex said &apos;but the NHS is richer than that&apos;.  The drug fixes the protein misfolding that causes the lung problems, so it keeps your lungs working so long as you keep taking it.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t@Soundbuy, there is an argument for introducing the US concept of a non-profit to the UK. Charity is a very loaded term.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tVertex previously cured Hepatitis C, but the second entrant in that market cured it better.  That was also a strikingly expensive drug and they got into a lot of trouble by comparing the price to that of the liver transplant the HCV victim might well otherwise need\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\t@pharma - agreed\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t@Mouselet, but that was a cure, so the cost, while large, was finite.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tpharma: indeed\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">wayneJ</span>\n\t\t\t\t\t\t\t\tBook value per share is pretty old fashioned but both total book value and tangible book value per share don&apos;t tell a great story. In essence, BE is spot on, hollowing the co to the altar of shareholder value ie pay dividends to the chinless wealth managers of Great Britain. (And don&apos;t mention some of the &apos;apparent&apos; earnings growth may be as it reports in USD and then translates into GBP). End of Rant - until the conference call love in.\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:44:26.000Z\" title=\"Thu Feb 14 2019 11:44:26 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:44:26 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:44 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550144681\" data-mid=\"1436527\" data-rawmessage=\"(@Mouselet: for non-work reasons, I&apos;ve learned a reasonable amount about the NICE approval model and I can say with some confidence that &quot;but you&apos;re big and can afford it&quot; isn&apos;t going to win the argument.)\" id=\"webchat-msg-1436527\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:44am</span></span><div class=\"messagebody\"><p>(@Mouselet: for non-work reasons, I&apos;ve learned a reasonable amount about the NICE approval model and I can say with some confidence that &quot;but you&apos;re big and can afford it&quot; isn&apos;t going to win the argument.)</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\t#Macro #US US: Core retail sales to rise 0.3% m/m in December &#x2013; Morgan Stanley\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\thttps://www.timesofmalta.com/articles/view/20190213/local/bank-of-valletta-goes-dark-after-detecting-cyber-attack.701896\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144717\" data-mid=\"1436528\" data-rawmessage=\"Restaurant Group mentioned earlier.\" id=\"webchat-msg-1436528\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:45am</span></span><div class=\"messagebody\"><p>Restaurant Group mentioned earlier.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tI think the argument will be quite long and quite loud, yes\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">doug43</span>\n\t\t\t\t\t\t\t\tmicrofocus\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">GBKrona</span>\n\t\t\t\t\t\t\t\t@WayneJ - great comments on pharmas - thank you\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144753\" data-mid=\"1436529\" data-rawmessage=\"Andy McCue is off due to &#x201C;extenuating personal circumstances.&#x201D;\" id=\"webchat-msg-1436529\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:45am</span></span><div class=\"messagebody\"><p>Andy McCue is off due to &#x201C;extenuating personal circumstances.&#x201D;</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t#Macro - anything on Germany avoiding recession? 0% growth a very convenient number.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\tAndy McCue FT story https://www.ft.com/content/2be65f8e-3030-11e9-8744-e7016697f225\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tbet he wishes he had realised he was worth &#xA3;100m\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:46:38.000Z\" title=\"Thu Feb 14 2019 11:46:38 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:46:38 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:46 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550144813\" data-mid=\"1436530\" data-rawmessage=\"They&apos;re extenuating personal circumstances that allow him to stay on for the moment, until a successor is found, so the suspicion is that extenuating personal circumstances might include not wanting to do the job any more.\" id=\"webchat-msg-1436530\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:46am</span></span><div class=\"messagebody\"><p>They&apos;re extenuating personal circumstances that allow him to stay on for the moment, until a successor is found, so the suspicion is that extenuating personal circumstances might include not wanting to do the job any more.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">DJ</span>\n\t\t\t\t\t\t\t\tany reason why Intu is creeping up?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tExtenuating seems a very odd adjective!\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tposes a lot of questions that phrase doesnt it!\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">red</span>\n\t\t\t\t\t\t\t\t@Pharmafrom what i hear so far this year things arent getting better. was at a meeting last night and spoke to a manager of a car upholstery factory which services a few manufacturers.\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550144897\" data-mid=\"1436531\" data-rawmessage=\"Here&apos;s Shore.\" id=\"webchat-msg-1436531\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:48am</span></span><div class=\"messagebody\"><p>Here&apos;s Shore.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\t@Pharma german finance ministry says there is upward impetus in the economy though I have looked hard to find it without success\n\t\t\t\t\t\t\t</div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550144902\" data-mid=\"1436532\" data-rawmessage=\"We note the statement from TRG this morning of CEO, Andy McCue, decision to leave the company due to extenuating personal circumstances. He will remain in position while his successor is recruited. Mr McCue was instrumental in the transformational acquisition of Wagamama and the acceleration of investment in the growth channels of travel concessions and pub restaurants; combined these three channels now account for some 70% of unit EBITDA. The  news is clearly disappointing from a TRG investor perspective, especially given how soon the announcement is post the Wagamama deal and the ongoing integration. We had hoped that the impending full year results (15th March) would have provided the platform for management to showcase the Wagamama opportunity and the potential to deliver material earnings growth over the medium term. Today&#x2019;s announcement will likely delay that staging point along with the likely drag on the share price. With our glass more than half full, the acquisition of Wagamama and investment in other growth channels has transformed the business and the shares appear cheap (forward PER of 11x, EV/EBITDA  of 7x and a dividend yield of 4.5%), TRG is clearly a more attractive opportunity for a prospective CEO than two years ago. We reiterate our BUY stance.\" id=\"webchat-msg-1436532\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:48am</span></span><div class=\"messagebody\"><blockquote><p>We note the statement from TRG this morning of CEO, Andy McCue, decision to leave the company due to extenuating personal circumstances. He will remain in position while his successor is recruited. Mr McCue was instrumental in the transformational acquisition of Wagamama and the acceleration of investment in the growth channels of travel concessions and pub restaurants; combined these three channels now account for some 70% of unit EBITDA. The  news is clearly disappointing from a TRG investor perspective, especially given how soon the announcement is post the Wagamama deal and the ongoing integration. We had hoped that the impending full year results (15th March) would have provided the platform for management to showcase the Wagamama opportunity and the potential to deliver material earnings growth over the medium term. Today&#x2019;s announcement will likely delay that staging point along with the likely drag on the share price. With our glass more than half full, the acquisition of Wagamama and investment in other growth channels has transformed the business and the shares appear cheap (forward PER of 11x, EV/EBITDA  of 7x and a dividend yield of 4.5%), TRG is clearly a more attractive opportunity for a prospective CEO than two years ago. We reiterate our BUY stance.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t@Mouselet - just thinking the same thing. Extenuating what? I think they reached for a Thesaurus.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\tBE - might it be that someone else does not want him to do the job anymore?\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:48:38.000Z\" title=\"Thu Feb 14 2019 11:48:38 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:48:38 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:48 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550144933\" data-mid=\"1436533\" data-rawmessage=\"And Liberum.\" id=\"webchat-msg-1436533\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:48am</span></span><div class=\"messagebody\"><p>And Liberum.</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550144937\" data-mid=\"1436534\" data-rawmessage=\"The timing of this announcement comes as a surprise given the recent &#xA3;559m acquisition of Wagamama and comes during the crucial stage of integration to deliver &#xA3;22m synergies promised, adding further instability and risk. We expect that the acquisition and deeply discounted rights issue process has taken its toll and contributed to his decision. The timing of this announcement may also lead to speculation that a turnaround in the core business is still a long way off.\n\nThe announcement comments that trading remains in line, FY18 results will be announced 15 March. Last month&#x2019;s trading update highlighted the continuing challenges across the Leisure brands which reported another dip in December with LFL sales declining -2.0% for FY18. We set out our Wagamama adjusted forecasts in our note published 17 January Read here. The acquisition of Wagamama transforms the growth profile of the combined group, but we remain concerned about the high price paid, resultant high gearing and integration risks, high potentially just got higher. The stock rating of 11.5x PE and 7.0x EV/EBITDA for CY19E, reflects these risks. HOLD.\" id=\"webchat-msg-1436534\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:48am</span></span><div class=\"messagebody\"><blockquote><p>The timing of this announcement comes as a surprise given the recent &#xA3;559m acquisition of Wagamama and comes during the crucial stage of integration to deliver &#xA3;22m synergies promised, adding further instability and risk. We expect that the acquisition and deeply discounted rights issue process has taken its toll and contributed to his decision. The timing of this announcement may also lead to speculation that a turnaround in the core business is still a long way off.</p>\n<p>The announcement comments that trading remains in line, FY18 results will be announced 15 March. Last month&#x2019;s trading update highlighted the continuing challenges across the Leisure brands which reported another dip in December with LFL sales declining -2.0% for FY18. We set out our Wagamama adjusted forecasts in our note published 17 January Read here. The acquisition of Wagamama transforms the growth profile of the combined group, but we remain concerned about the high price paid, resultant high gearing and integration risks, high potentially just got higher. The stock rating of 11.5x PE and 7.0x EV/EBITDA for CY19E, reflects these risks. HOLD.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\t@mouselet be interesting to see the average share price performance of companies where CEOs leave suddenly from extenuating circs...\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Pharma: their lawyers have gone over this, trying to avoid a shareholders&apos; lawsuit?\n\t\t\t\t\t\t\t</div><div class=\"msg separator has-headshot\" data-timestamp=\"1550145028\" data-mid=\"1436535\" data-rawmessage=\"11:50AM\" id=\"webchat-msg-1436535\">\n\t<div class=\"messagebody\"><time class=\"o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:50:28.000Z\" title=\"Thu Feb 14 2019 11:50:28 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:50:28 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\tundefined\n\t\t\t\t\t\t\t\t</time></div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t@A.M. Yes, implies there is an unwelcome reason for his leaving, but that there is a partial excuse\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Pharma: I guess we can speculate, but that would invite zapping from above.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Sails</span>\n\t\t\t\t\t\t\t\tCan I just point out that to &quot; pay dividends to the chinless wealth managers of Great Britain&quot; is also funding the pensions of the grey-haired pensioners of Great Britain?\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:51:50.000Z\" title=\"Thu Feb 14 2019 11:51:50 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:51:50 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:51 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145125\" data-mid=\"1436536\" data-rawmessage=\"Okay, what else?\" id=\"webchat-msg-1436536\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:52am</span></span><div class=\"messagebody\"><p>Okay, what else?</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\tre RTN how many people believe that thy will make  a success of running Wagamama having been fortunate to have visited Frankie and Bennys I am not one  of them\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\t&apos;extenuating personal circumstances&apos; seems to be the HR term currently used for &apos;compassionate leave&apos;\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tah fair enough\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">red</span>\n\t\t\t\t\t\t\t\tretail sales, cant find too much interesting apart from forecast ranges depending on how close to/far from f/c it is. think a bit on wide side imo so wont post.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\tMicro Focus?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Mouselet: ah.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tM&amp;A chatter all very quiet.........hmmmm....... (throws out the bait)\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145235\" data-mid=\"1436537\" data-rawmessage=\"......... Micro Focus? Sure. It&apos;s not as bad as it could be.\" id=\"webchat-msg-1436537\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:53am</span></span><div class=\"messagebody\"><p>......... Micro Focus? Sure. It&apos;s not as bad as it could be.</p>\n</div></div><div class=\"msg price has-headshot\" data-timestamp=\"1550145244\" data-mid=\"1436538\" data-rawmessage=\"&lt;strong&gt;Micro Focus International PLC (MCRO:LSE):&lt;/strong&gt; Last: 1,717, up 199.5 (+13.15%), High: 1,746, Low: 1,568, Volume: 1.56m\" id=\"webchat-msg-1436538\">\n\t<div class=\"messagebody\"><strong>Micro Focus International PLC (MCRO:LSE):</strong> Last: 1,717, up 199.5 (+13.15%), High: 1,746, Low: 1,568, Volume: 1.56m</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Pharma</span>\n\t\t\t\t\t\t\t\t#HR - we are watching the evolution of a whole new language in real time.\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t@Pharma: corporate newspeak..\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">JulioIgelsias</span>\n\t\t\t\t\t\t\t\t@pharma - was a funny BBC sport piece on that re Football managers and unpicking the standard lingo\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:54:41.000Z\" title=\"Thu Feb 14 2019 11:54:41 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:54:41 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:54 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145296\" data-mid=\"1436539\" data-rawmessage=\"The good news -- and you really need to see this in the context of how bad the news was previously -- is that was H2 licences were only down 8%.\" id=\"webchat-msg-1436539\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:54am</span></span><div class=\"messagebody\"><p>The good news -- and you really need to see this in the context of how bad the news was previously -- is that was H2 licences were only down 8%.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">red</span>\n\t\t\t\t\t\t\t\tus ppi also to watch, may take away any air from retail sales esp if soft as f/c\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145344\" data-mid=\"1436540\" data-rawmessage=\"Here&apos;s Goldman.\" id=\"webchat-msg-1436540\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:55am</span></span><div class=\"messagebody\"><p>Here&apos;s Goldman.</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550145350\" data-mid=\"1436541\" data-rawmessage=\"Key positives for us in Micro Focus&#x2019; FY18 results were: 1) Strong topline performance in FY18 and a better than expected FY19 revenue guidance suggesting improvement in sales execution; 2) EBITDA margin ahead of expectations; 3) Continued focus on cash returns. We expect a positive share price reaction given the strong set of FY18 results and an encouraging FY19 guidance.\nTopline declines stabilising: The total revenue organic growth in FY18 came at\nn-5.3%, above the company guidance (a decline of -6%to -9%) as well as GSe / consensus expectations of c.-7%. Core Micro Focus (ex-SUSE) posted -7% growth in FY18 and the -4% to -6% FY19 guidance indicates revenue declines are moderating, suggesting improvement in execution. The key positive for us was the strong license performance which came in at c.-8% yoy in 2HFY18, a significant improvement vs -18% yoy organic growth in 1HFY18.\nEBITDA margins ahead: Core MF EBITDA came in ahead of expectations,\nnwhich we believe was driven by flow through of better-than-expected license performance as well as cost synergies from HPE integration.\nContinued focus on cash returns: Micro Focus continues to focus on returning\nncash to shareholders with an increase in the buyback of $110mn (before SUSE payout) taking the total buyback to $510mn, suggesting the strong cash generative nature of the business. The company highlighted that excess cash from the proposed SUSE sale post tax and debt repayment will be returned to shareholders.\" id=\"webchat-msg-1436541\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:55am</span></span><div class=\"messagebody\"><blockquote><p>Key positives for us in Micro Focus&#x2019; FY18 results were: 1) Strong topline performance in FY18 and a better than expected FY19 revenue guidance suggesting improvement in sales execution; 2) EBITDA margin ahead of expectations; 3) Continued focus on cash returns. We expect a positive share price reaction given the strong set of FY18 results and an encouraging FY19 guidance.<br>\nTopline declines stabilising: The total revenue organic growth in FY18 came at<br>\nn-5.3%, above the company guidance (a decline of -6%to -9%) as well as GSe / consensus expectations of c.-7%. Core Micro Focus (ex-SUSE) posted -7% growth in FY18 and the -4% to -6% FY19 guidance indicates revenue declines are moderating, suggesting improvement in execution. The key positive for us was the strong license performance which came in at c.-8% yoy in 2HFY18, a significant improvement vs -18% yoy organic growth in 1HFY18.<br>\nEBITDA margins ahead: Core MF EBITDA came in ahead of expectations,<br>\nnwhich we believe was driven by flow through of better-than-expected license performance as well as cost synergies from HPE integration.<br>\nContinued focus on cash returns: Micro Focus continues to focus on returning<br>\nncash to shareholders with an increase in the buyback of $110mn (before SUSE payout) taking the total buyback to $510mn, suggesting the strong cash generative nature of the business. The company highlighted that excess cash from the proposed SUSE sale post tax and debt repayment will be returned to shareholders.</p></blockquote>\n</div></div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:56:09.000Z\" title=\"Thu Feb 14 2019 11:56:09 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:56:09 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:56 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145384\" data-mid=\"1436542\" data-rawmessage=\"And Numis.\" id=\"webchat-msg-1436542\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:56am</span></span><div class=\"messagebody\"><p>And Numis.</p>\n</div></div><div class=\"msg blockquote has-headshot\" data-timestamp=\"1550145400\" data-mid=\"1436543\" data-rawmessage=\"Micro Focus has outperformed year-end guidance both in revenue and cash terms. Continuing operations&apos; revenues were -5.0% CCY in the 6m to October 2018, after -8.7% in the prior 6m. Net debt of $4.25b at Oct-18 was also ahead. Guidance for underlying CCY revenues of -4% to -6% in FY19, combined with outperformance in FY18, should we think lead to consensus revenue and EBITDA upgrades for FY19 of c.3%. While there remains significant work still to do, we view these results as another significant step in the rehabilitation of Micro Focus. We believe that the shares can continue to perform strongly, with the next significant event being the sale of SUSE by end March and subsequent capital return.\" id=\"webchat-msg-1436543\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:56am</span></span><div class=\"messagebody\"><blockquote><p>Micro Focus has outperformed year-end guidance both in revenue and cash terms. Continuing operations&apos; revenues were -5.0% CCY in the 6m to October 2018, after -8.7% in the prior 6m. Net debt of $4.25b at Oct-18 was also ahead. Guidance for underlying CCY revenues of -4% to -6% in FY19, combined with outperformance in FY18, should we think lead to consensus revenue and EBITDA upgrades for FY19 of c.3%. While there remains significant work still to do, we view these results as another significant step in the rehabilitation of Micro Focus. We believe that the shares can continue to perform strongly, with the next significant event being the sale of SUSE by end March and subsequent capital return.</p></blockquote>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">A. M.</span>\n\t\t\t\t\t\t\t\t(@BE: thanks for today&apos;s session)\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mouselet</span>\n\t\t\t\t\t\t\t\tThank you BE\n\t\t\t\t\t\t\t</div><div class=\"msg separator has-headshot\" data-timestamp=\"1550145439\" data-mid=\"1436544\" data-rawmessage=\"11:57AM\" id=\"webchat-msg-1436544\">\n\t<div class=\"messagebody\"><time class=\"o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:57:19.000Z\" title=\"Thu Feb 14 2019 11:57:19 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:57:19 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\tundefined\n\t\t\t\t\t\t\t\t</time></div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">SupposeToBeWorking...</span>\n\t\t\t\t\t\t\t\tThanks all\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:57:27.000Z\" title=\"Thu Feb 14 2019 11:57:27 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:57:27 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:57 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145462\" data-mid=\"1436545\" data-rawmessage=\"@Soundbuy: yes, M&amp;A is very quiet since you ask.\" id=\"webchat-msg-1436545\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:57am</span></span><div class=\"messagebody\"><p>@Soundbuy: yes, M&amp;A is very quiet since you ask.</p>\n</div></div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145487\" data-mid=\"1436546\" data-rawmessage=\"There are a few constants, such as Rentokil looking at doing something big in the US ......\" id=\"webchat-msg-1436546\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:58am</span></span><div class=\"messagebody\"><p>There are a few constants, such as Rentokil looking at doing something big in the US ......</p>\n</div></div><div class=\"msg price has-headshot\" data-timestamp=\"1550145492\" data-mid=\"1436547\" data-rawmessage=\"&lt;strong&gt;Rentokil Initial PLC (RTO:LSE):&lt;/strong&gt; Last: 353.20, up 1.7 (+0.48%), High: 354.90, Low: 350.80, Volume: 1.17m\" id=\"webchat-msg-1436547\">\n\t<div class=\"messagebody\"><strong>Rentokil Initial PLC (RTO:LSE):</strong> Last: 353.20, up 1.7 (+0.48%), High: 354.90, Low: 350.80, Volume: 1.17m</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">DJ</span>\n\t\t\t\t\t\t\t\tthx all\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T11:58:40.000Z\" title=\"Thu Feb 14 2019 11:58:40 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 11:58:40 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t11:58 am\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145535\" data-mid=\"1436548\" data-rawmessage=\"And the stuff I mentioned yesterday regarding Jones Lang LaSalle being on the hunt.\" id=\"webchat-msg-1436548\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">11:58am</span></span><div class=\"messagebody\"><p>And the stuff I mentioned yesterday regarding Jones Lang LaSalle being on the hunt.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">1966AndAllThat</span>\n\t\t\t\t\t\t\t\tIf China property in crisis what western regulated opportunities are there to profit from it? (And don&apos;t say B*****n)\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Excel Developer</span>\n\t\t\t\t\t\t\t\t#Macro China Exports grow despite weak US-China component.\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145626\" data-mid=\"1436549\" data-rawmessage=\"Oh, and I think Talend -- US cloud computing thing -- has Q4 numbers due after the bell tonight, which might be of interest to some.\" id=\"webchat-msg-1436549\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">12:00pm</span></span><div class=\"messagebody\"><p>Oh, and I think Talend -- US cloud computing thing -- has Q4 numbers due after the bell tonight, which might be of interest to some.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Blank canvas</span>\n\t\t\t\t\t\t\t\tthanks for everything today BE\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">FATDAZ</span>\n\t\t\t\t\t\t\t\tjumping off, so thanks all speak tomorrow\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145735\" data-mid=\"1436551\" data-rawmessage=\"But anyway, that&apos;s us at midday and there&apos;s too many conversations happening offscreen to concentrate on what&apos;s happening onscreen.\" id=\"webchat-msg-1436551\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">12:02pm</span></span><div class=\"messagebody\"><p>But anyway, that&apos;s us at midday and there&apos;s too many conversations happening offscreen to concentrate on what&apos;s happening onscreen.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Soundbuy</span>\n\t\t\t\t\t\t\t\tThanks.............\n\t\t\t\t\t\t\t</div><time class=\"marketslive-timestamp o-date\" data-o-component=\"o-date\" data-o-date-format=\"h:mm a\" datetime=\"2019-02-14T12:02:31.000Z\" title=\"Thu Feb 14 2019 12:02:31 GMT+0000 (UTC)\" aria-label=\"Thu Feb 14 2019 12:02:31 GMT+0000 (UTC)\">\n\t\t\t\t\t\t\t\t\t\t12:02 pm\n\t\t\t\t\t\t\t\t</time><div class=\"msg normal has-headshot\" data-timestamp=\"1550145766\" data-mid=\"1436552\" data-rawmessage=\"Head over here for more stuff. Chemring, Ashmore, .... other stuff: https://www.ft.com/stocks-to-watch\" id=\"webchat-msg-1436552\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">12:02pm</span></span><div class=\"messagebody\"><p>Head over here for more stuff. Chemring, Ashmore, .... other stuff: <a href=\"https://www.ft.com/stocks-to-watch\" target=\"_blank\">https://www.ft.com/stocks-to-watch</a></p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">BornCynic</span>\n\t\t\t\t\t\t\t\tThanks BE / ROTR\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145801\" data-mid=\"1436553\" data-rawmessage=\"Ta for the comments. Back tomorrow. I assume.\" id=\"webchat-msg-1436553\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">12:03pm</span></span><div class=\"messagebody\"><p>Ta for the comments. Back tomorrow. I assume.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">GBKrona</span>\n\t\t\t\t\t\t\t\tthanks all\n\t\t\t\t\t\t\t</div><div class=\"msg normal has-headshot\" data-timestamp=\"1550145816\" data-mid=\"1436554\" data-rawmessage=\"Afternoon all.\" id=\"webchat-msg-1436554\">\n\t<span class=\"messageheader\"><span class=\"participant color-1\">BE</span><span class=\"timestamp\">12:03pm</span></span><div class=\"messagebody\"><p>Afternoon all.</p>\n</div></div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Flaneur</span>\n\t\t\t\t\t\t\t\t@1966 - china crisis? link?\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t<div class=\"marketslive-user-comment\">\n\t\t\t\t\t\t\t\t<span class=\"marketslive-user-comment-pseudonym\">Mr Ticker</span>\n\t\t\t\t\t\t\t\tCheers BE\n\t\t\t\t\t\t\t</div></div>",
  "authors": [
    {
      "name": "Bryce Elder",
      "headshotUrl": "https://www.ft.com/__origami/service/image/v2/images/raw/fthead:bryce-elder?source=alphaville",
      "isAlphavilleEditor": true,
      "url": "/author/Bryce%20Elder"
    }
  ],
  "primaryTheme": [
    {
      "label": "Markets Live",
      "url": "/marketslive"
    }
  ],
  "originalTitle": "Markets Live: Thursday, 14th February 2019",
  "isLive": false,
  "subheading": "Live markets commentary from FT.com",
  "standfirst": "Live markets commentary from FT.com"
}
